Johnson & Johnson (JNJ) Announces $0.90 Quarterly Dividend

Share on StockTwits

Johnson & Johnson (NYSE:JNJ) announced a quarterly dividend on Thursday, October 18th, RTT News reports. Investors of record on Tuesday, November 27th will be given a dividend of 0.90 per share on Tuesday, December 11th. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. The ex-dividend date of this dividend is Monday, November 26th.

Johnson & Johnson has raised its dividend payment by an average of 6.4% annually over the last three years and has increased its dividend annually for the last 55 consecutive years. Johnson & Johnson has a dividend payout ratio of 44.2% meaning its dividend is sufficiently covered by earnings. Research analysts expect Johnson & Johnson to earn $8.66 per share next year, which means the company should continue to be able to cover its $3.60 annual dividend with an expected future payout ratio of 41.6%.

Shares of NYSE JNJ traded up $0.04 during mid-day trading on Friday, hitting $145.34. 5,343,128 shares of the stock traded hands, compared to its average volume of 7,921,995. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a twelve month low of $118.62 and a twelve month high of $148.32. The company has a market cap of $388.35 billion, a price-to-earnings ratio of 19.91, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The company had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. During the same quarter last year, the business posted $1.90 EPS. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on the company. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, July 15th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Raymond James lifted their target price on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $142.54.

In other news, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Insiders have sold a total of 85,340 shares of company stock worth $11,992,396 over the last ninety days. Company insiders own 0.22% of the company’s stock.

Several hedge funds have recently bought and sold shares of JNJ. Phocas Financial Corp. raised its position in shares of Johnson & Johnson by 999,927.7% in the 2nd quarter. Phocas Financial Corp. now owns 129,463,583 shares of the company’s stock worth $1,571,000 after acquiring an additional 129,450,637 shares in the last quarter. Glenmede Trust Co. NA increased its position in Johnson & Johnson by 149.8% in the 2nd quarter. Glenmede Trust Co. NA now owns 22,174,682 shares of the company’s stock valued at $2,690,676,000 after buying an additional 13,295,992 shares in the last quarter. Charles Schwab Investment Advisory Inc. bought a new stake in Johnson & Johnson in the 2nd quarter valued at about $383,285,000. BlackRock Inc. increased its position in Johnson & Johnson by 1.7% in the 2nd quarter. BlackRock Inc. now owns 178,310,265 shares of the company’s stock valued at $21,636,166,000 after buying an additional 2,921,241 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Johnson & Johnson by 191.2% in the 2nd quarter. Renaissance Technologies LLC now owns 3,740,300 shares of the company’s stock valued at $453,848,000 after buying an additional 2,455,901 shares in the last quarter. 66.60% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://baseballnewssource.com/2018/11/10/johnson-johnson-jnj-announces-0-90-quarterly-dividend/2847187.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Why is the ex-dividend date different from the record date?

Dividend History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.